JP7496917B2 - Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン - Google Patents
Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン Download PDFInfo
- Publication number
- JP7496917B2 JP7496917B2 JP2023108177A JP2023108177A JP7496917B2 JP 7496917 B2 JP7496917 B2 JP 7496917B2 JP 2023108177 A JP2023108177 A JP 2023108177A JP 2023108177 A JP2023108177 A JP 2023108177A JP 7496917 B2 JP7496917 B2 JP 7496917B2
- Authority
- JP
- Japan
- Prior art keywords
- kras
- dose
- pharma
- acceptable salt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102200006538 rs121913530 Human genes 0.000 title claims description 865
- 239000003112 inhibitor Substances 0.000 title claims description 101
- 150000003839 salts Chemical class 0.000 claims description 834
- 206010028980 Neoplasm Diseases 0.000 claims description 810
- 150000001875 compounds Chemical class 0.000 claims description 733
- 238000011282 treatment Methods 0.000 claims description 572
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 407
- 201000011510 cancer Diseases 0.000 claims description 368
- 238000000034 method Methods 0.000 claims description 313
- 229960002621 pembrolizumab Drugs 0.000 claims description 277
- 229960005079 pemetrexed Drugs 0.000 claims description 198
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical group C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 198
- 239000003814 drug Substances 0.000 claims description 197
- 238000004519 manufacturing process Methods 0.000 claims description 124
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical group [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 112
- 229960004562 carboplatin Drugs 0.000 claims description 112
- 229960004316 cisplatin Drugs 0.000 claims description 100
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 100
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 96
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 96
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims description 66
- 230000002829 reductive effect Effects 0.000 claims description 62
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 50
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 50
- 229940124597 therapeutic agent Drugs 0.000 claims description 50
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 46
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 36
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 36
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 36
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 36
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 36
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 32
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 32
- 201000002528 pancreatic cancer Diseases 0.000 claims description 32
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 32
- 206010009944 Colon cancer Diseases 0.000 claims description 27
- 230000000750 progressive effect Effects 0.000 claims description 26
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 24
- 229910052697 platinum Inorganic materials 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 229940121647 egfr inhibitor Drugs 0.000 claims description 22
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 19
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 19
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 19
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 19
- 239000012824 ERK inhibitor Substances 0.000 claims description 19
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 17
- 239000004052 folic acid antagonist Substances 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 230000003432 anti-folate effect Effects 0.000 claims description 2
- 229940127074 antifolate Drugs 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 description 151
- 102100030708 GTPase KRas Human genes 0.000 description 77
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 77
- 102000008096 B7-H1 Antigen Human genes 0.000 description 73
- 108010074708 B7-H1 Antigen Proteins 0.000 description 73
- 229940125399 kras g12c inhibitor Drugs 0.000 description 61
- 230000004044 response Effects 0.000 description 43
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 description 29
- 229940125811 TNO155 Drugs 0.000 description 29
- YQQZZYYQTCPEAS-OYLFLEFRSA-N ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F Chemical compound ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F YQQZZYYQTCPEAS-OYLFLEFRSA-N 0.000 description 28
- 229960005395 cetuximab Drugs 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 24
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 23
- 229950001573 abemaciclib Drugs 0.000 description 23
- 229960001433 erlotinib Drugs 0.000 description 23
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 23
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 23
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 23
- 201000010099 disease Diseases 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 13
- 230000035772 mutation Effects 0.000 description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 208000029523 Interstitial Lung disease Diseases 0.000 description 9
- 230000002411 adverse Effects 0.000 description 9
- -1 aminopyridine compound Chemical class 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- HGYTYZKWKUXRKA-MRXNPFEDSA-N 1-[4-[3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]sulfanyl-3,3-difluoro-2H-indol-1-yl]ethanone Chemical group NC=1C(=NC=C(N=1)N1CCC2([C@@H](COC2)N)CC1)SC1=C2C(CN(C2=CC=C1)C(C)=O)(F)F HGYTYZKWKUXRKA-MRXNPFEDSA-N 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 229940126002 RMC-4630 Drugs 0.000 description 6
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000011225 antiretroviral therapy Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- RGCGBFIARQENML-JOCHJYFZSA-N (3R)-1'-[3-(3,4-dihydro-2H-1,5-naphthyridin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]spiro[3H-1-benzofuran-2,4'-piperidine]-3-amine Chemical compound N[C@@H]1c2ccccc2OC11CCN(CC1)c1cnc2c(n[nH]c2n1)N1CCCc2ncccc12 RGCGBFIARQENML-JOCHJYFZSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 101150105104 Kras gene Proteins 0.000 description 4
- 229940126000 RLY-1971 Drugs 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960003852 atezolizumab Drugs 0.000 description 4
- 229950002916 avelumab Drugs 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229950009791 durvalumab Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical group O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- AMADCPJVPLUGQO-UHFFFAOYSA-N 1-[3-(2,3-dichlorophenyl)-2H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methylpiperidin-4-amine Chemical compound ClC1=C(C=CC=C1Cl)C1=NNC2=NC(=CN=C21)N1CCC(CC1)(N)C AMADCPJVPLUGQO-UHFFFAOYSA-N 0.000 description 3
- UNCWHIJFMMDYME-UHFFFAOYSA-N 3-[2-(2-nitrophenyl)hydrazinyl]-2-oxoindole-5-sulfonic acid Chemical compound C=12C=C(S(=O)(=O)O)C=CC2=NC(=O)C=1NNC1=CC=CC=C1[N+]([O-])=O UNCWHIJFMMDYME-UHFFFAOYSA-N 0.000 description 3
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical group CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 3
- GVHLZSZTHCBBFC-UHFFFAOYSA-N 4-[[2,5-bis(4-nitrophenyl)-3-oxo-1H-pyrazol-4-yl]diazenyl]benzenesulfonic acid Chemical compound C1=CC(=CC=C1C2=C(C(=O)N(N2)C3=CC=C(C=C3)[N+](=O)[O-])N=NC4=CC=C(C=C4)S(=O)(=O)O)[N+](=O)[O-] GVHLZSZTHCBBFC-UHFFFAOYSA-N 0.000 description 3
- IYPHPQODKSHEHV-UHFFFAOYSA-N 4-[[5-(4-nitrophenyl)-3-oxo-2-phenyl-1H-pyrazol-4-yl]diazenyl]benzenesulfonic acid Chemical group C1=CC=C(C=C1)N2C(=O)C(=C(N2)C3=CC=C(C=C3)[N+](=O)[O-])N=NC4=CC=C(C=C4)S(=O)(=O)O IYPHPQODKSHEHV-UHFFFAOYSA-N 0.000 description 3
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical group C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 3
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical group NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 3
- URUPFUYPXLMTMT-KPZWWZAWSA-N 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-[3-chloro-2-(cyclopropylamino)pyridin-4-yl]-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@@H]1OCC2(CCN(CC2)c2nc3n[nH]c(-c4ccnc(NC5CC5)c4Cl)c3c(=O)n2C)[C@@H]1N URUPFUYPXLMTMT-KPZWWZAWSA-N 0.000 description 3
- QZHZIDHAIVAHMD-SMDDNHRTSA-N 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C)=O)SC=1C(=NC=CC=1)C(F)(F)F QZHZIDHAIVAHMD-SMDDNHRTSA-N 0.000 description 3
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical group N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 3
- 101100387225 Buchnera aphidicola subsp. Baizongia pistaciae (strain Bp) asd gene Proteins 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000002633 Febrile Neutropenia Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical group C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- XGMFVZOKHBRUTL-QURGRASLSA-N OC1=C(C=C(C2=CC=CN=C12)S(O)(=O)=O)\N=N\C1=CC=C2C=C(C=CC2=C1)S(O)(=O)=O Chemical group OC1=C(C=C(C2=CC=CN=C12)S(O)(=O)=O)\N=N\C1=CC=C2C=C(C=CC2=C1)S(O)(=O)=O XGMFVZOKHBRUTL-QURGRASLSA-N 0.000 description 3
- 206010061137 Ocular toxicity Diseases 0.000 description 3
- 229940125999 RMC-4550 Drugs 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical group N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 229960001686 afatinib Drugs 0.000 description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical group N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 3
- 229950009447 alisertib Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000005441 aurora Substances 0.000 description 3
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical group C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 3
- 229960003202 cefsulodin Drugs 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 231100000226 haematotoxicity Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 231100001158 immune-related toxicity Toxicity 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 231100000327 ocular toxicity Toxicity 0.000 description 3
- 229960004390 palbociclib Drugs 0.000 description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 229950003687 ribociclib Drugs 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229940121497 sintilimab Drugs 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229950000185 tozasertib Drugs 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 229940123414 Folate antagonist Drugs 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 2
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 229940124785 KRAS inhibitor Drugs 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010054184 Small intestine carcinoma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 108091092240 circulating cell-free DNA Proteins 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000031128 Upper tract urothelial carcinoma Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940124988 adagrasib Drugs 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000025106 carcinoma of duodenum Diseases 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 229950002966 danusertib Drugs 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940121432 dostarlimab Drugs 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 201000003747 jejunal adenocarcinoma Diseases 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000015325 multicentric Castleman disease Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000005969 oncogenic driver mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940018007 retifanlimab Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 229960001266 typhoid vaccines Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024086236A JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263357227P | 2022-06-30 | 2022-06-30 | |
| US63/357,227 | 2022-06-30 | ||
| US202363486785P | 2023-02-24 | 2023-02-24 | |
| US63/486,785 | 2023-02-24 | ||
| US202363496447P | 2023-04-17 | 2023-04-17 | |
| US63/496,447 | 2023-04-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086236A Division JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024007504A JP2024007504A (ja) | 2024-01-18 |
| JP2024007504A5 JP2024007504A5 (https=) | 2024-04-05 |
| JP7496917B2 true JP7496917B2 (ja) | 2024-06-07 |
Family
ID=87468549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108177A Active JP7496917B2 (ja) | 2022-06-30 | 2023-06-30 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
| JP2024086236A Pending JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086236A Pending JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240108618A1 (https=) |
| EP (1) | EP4547251A1 (https=) |
| JP (2) | JP7496917B2 (https=) |
| KR (1) | KR20250027777A (https=) |
| CN (1) | CN119907671A (https=) |
| CA (1) | CA3260047A1 (https=) |
| IL (1) | IL317823A (https=) |
| MA (1) | MA71325A (https=) |
| MX (1) | MX2025000105A (https=) |
| WO (1) | WO2024006424A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021222333A1 (en) | 2020-04-30 | 2021-11-04 | Genentech, Inc. | Kras specific antibodies and uses thereof |
| JP2022508469A (ja) | 2019-12-11 | 2022-01-19 | イーライ リリー アンド カンパニー | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20230285498A1 (en) * | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
| EP4486345A1 (en) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
-
2023
- 2023-06-29 EP EP23745331.1A patent/EP4547251A1/en active Pending
- 2023-06-29 KR KR1020257002609A patent/KR20250027777A/ko active Pending
- 2023-06-29 IL IL317823A patent/IL317823A/en unknown
- 2023-06-29 CN CN202380063188.1A patent/CN119907671A/zh active Pending
- 2023-06-29 US US18/344,134 patent/US20240108618A1/en active Pending
- 2023-06-29 WO PCT/US2023/026554 patent/WO2024006424A1/en not_active Ceased
- 2023-06-29 CA CA3260047A patent/CA3260047A1/en active Pending
- 2023-06-29 MA MA71325A patent/MA71325A/fr unknown
- 2023-06-30 JP JP2023108177A patent/JP7496917B2/ja active Active
-
2024
- 2024-05-28 JP JP2024086236A patent/JP2024112968A/ja active Pending
-
2025
- 2025-01-06 MX MX2025000105A patent/MX2025000105A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022508469A (ja) | 2019-12-11 | 2022-01-19 | イーライ リリー アンド カンパニー | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2021222333A1 (en) | 2020-04-30 | 2021-11-04 | Genentech, Inc. | Kras specific antibodies and uses thereof |
| WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| MA71325A (fr) | 2025-04-30 |
| CN119907671A (zh) | 2025-04-29 |
| US20240108618A1 (en) | 2024-04-04 |
| CA3260047A1 (en) | 2024-01-04 |
| AU2023297941A1 (en) | 2025-01-16 |
| MX2025000105A (es) | 2025-02-10 |
| JP2024007504A (ja) | 2024-01-18 |
| KR20250027777A (ko) | 2025-02-27 |
| WO2024006424A1 (en) | 2024-01-04 |
| JP2024112968A (ja) | 2024-08-21 |
| IL317823A (en) | 2025-02-01 |
| TW202421145A (zh) | 2024-06-01 |
| EP4547251A1 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7496917B2 (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン | |
| EP3142751B1 (en) | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| CN114245753A (zh) | 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合 | |
| JP2019517507A (ja) | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| CN107949401A (zh) | 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物 | |
| EP4159238A1 (en) | Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody | |
| TWI921668B (zh) | Kras g12c抑制劑之給藥方案 | |
| CN112915202B (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| TW202320790A (zh) | 治療癌症之方法 | |
| AU2023297941B2 (en) | Kras g12c inhibitor for treating cancer | |
| US12611403B2 (en) | Combined pharmaceutical composition of c-Met kinase inhibitor and anti-PD-L1 antibody | |
| JP2022522994A (ja) | がんの処置のための組合せ物 | |
| JP2025524957A (ja) | 抗ＧＡＲＰ－ＴＧＦ－β１／ＰＤ－１併用療法 | |
| Tintelnot et al. | Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases—the IKF-080/AIO-QUINTIS trial | |
| TW202535407A (zh) | 治療癌症的方法 | |
| TW202547503A (zh) | 於癌症的治療中之ｐｍ１４和拓樸異構酶ｉ抑制劑的組合 | |
| TW202608446A (zh) | 依維替定（ｅｃｕｂｅｃｔｅｄｉｎ）於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 | |
| CN120346313A (zh) | 治疗肿瘤的药物组合 | |
| CN117460534A (zh) | 基于cd47抑制物质、免疫检查点抑制物质和标准疗法的联用的癌症治疗方法 | |
| HK40070611A (en) | Combination of anti-her2 antibody and cdk inhibitor for tumor treatment | |
| CN114470190A (zh) | 喹啉衍生物与pd-1单抗的药物组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240328 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240328 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240409 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240425 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240528 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7496917 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |